Associated Papers
Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology.
Echeverría-Garcés G et al.
Frontiers in Pharmacology, 2024
A review of HER2 overexpression and somatic mutations in cancers.
Galogre M et al.
Critical Reviews in Oncology/hematology, 2023
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
35503682 (PubMed )
Supplement: can-21-0940_supplementary_data_suppsd.docx
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
31034466 (PubMed )
Supplement: pcbi.1006981.s010.xlsx › final_benchmark
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.
Casolari DA et al.
Scientific Reports, 2017
How is Herstatin, a tumor suppressor splice variant of the oncogene HER2, regulated?
Silipo M et al.
Rna Biology, 2017
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
de Martino M et al.
Cancer Biology & Therapy, 2014
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Unknown Author
Nature, 2008
Select a paper to view details